Cresemba Evropska unija - slovenščina - EMA (European Medicines Agency)

cresemba

basilea pharmaceutica deutschland gmbh - isavukonazol - aspergiloza - cresemba je navedeno pri odraslih za zdravljenje:invazivne aspergillosismucormycosis pri bolnikih, za katere amphotericin b je inappropriateconsideration treba uradna smernice za ustrezno uporabo protiglivično agenti.

Lojuxta Evropska unija - slovenščina - EMA (European Medicines Agency)

lojuxta

amryt pharmaceuticals dac - lomitapide - hiperholesterolemija - sredstva za spreminjanje lipidov - lojuxta je navedena kot dodatek k dieti low‑fat in drugimi lipid‑lowering zdravili z ali brez citofereza nizko gostoto lipoproteinov (ldl), pri odraslih bolnikih s homozigotno družinsko hiperholesterolemijo (hofh). genetske potrditev hofh, je treba pridobiti, kadar je to mogoče. druge oblike primarne hyperlipoproteinaemia in sekundarne vzroke hypercholesterolaemia (e. nephrotic sindrom, hipotiroidizem) mora biti izključena.

Pifeltro Evropska unija - slovenščina - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - okužbe z virusom hiv - antivirusi za sistemsko uporabo - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

CIKLOSPORIN ALKALOID-INT 25 mg mehke kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciklosporin alkaloid-int 25 mg mehke kapsule

alkaloid - int d.o.o. - ciklosporin - kapsula, mehka - ciklosporin 25 mg / 1 kapsula - ciklosporin

CIKLOSPORIN ALKALOID-INT 50 mg mehke kapsule Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ciklosporin alkaloid-int 50 mg mehke kapsule

alkaloid - int d.o.o. - ciklosporin - kapsula, mehka - ciklosporin 50 mg / 1 kapsula - ciklosporin

Brukinsa Evropska unija - slovenščina - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).